It is interesting to note that, although CHEK2 interacts with BRCA1 in the same pathway, its mutations are significantly associated with estrogen receptor positive breast tumours, indicating an impact on tumour etiology that is different from BRCA1. This evidence concerns the gene ESR1 and breast neoplasm.